Excessive daytime sleepiness Market is predicted to reach USD 9.72 billion at a CAGR of 7.20% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Excessive daytime sleepiness Market”.

The excessive daytime sleepiness market is estimated to register a CAGR of 7.20%during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the excessive daytime sleepiness market—Teva Pharmaceutical Industries Ltd.,GE Healthcare , Jazz Pharmaceuticals, Compumedics Fisher & Paykel Healthcare, BIOPROJET, BMC Medical Co. Ltd., Avadel Pharmaceuticals plc , Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer.

Market Highlights

The excessive daytime sleepiness market is accounted to register a CAGR of 7.20%during the forecast period and is estimated to reach USD 9.72 billion by 2032.

The excessive daytime sleepiness market is driven by factors such as increasing prevalence of sleep disorders and rising awareness about their impact on overall health. Opportunities lie in the development of novel treatment options and diagnostic techniques to address the unmet medical needs. However, challenges include the lack of accurate diagnostic tools, limited treatment options, and the stigma associated with sleep disorders, hindering market growth and patient care.

Access full report @ https://www.marketresearchfuture.com/reports/excessive-daytime-sleepiness-market-20304

Segment Analysis

The excessive daytime sleepiness market has been segmented based Diseases, Treatment and Distribution channels.

On the basis of Diseases, the market is segmented into Obstructive Sleep Apnea (OSA), Narcolepsy. The obstructive sleep apnea (OSA) segment was attributed to holding the largest market share in 2022. This condition affects millions of individuals worldwide and is associated with various health complications, including cardiovascular diseases, hypertension, and impaired cognitive function. Due to its widespread prevalence and significant impact on overall health and well-being, OSA remains the primary focus of diagnosis, treatment, and management efforts within the Excessive Daytime Sleepiness market.

Based on Treatment, the excessive daytime sleepiness market has been segmented into Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate). Therapeutic Drugs segment was attributed to holding the largest market share in 2022. This encompasses a range of pharmaceutical interventions aimed at managing and alleviating symptoms associated with various sleep disorders contributing to excessive daytime sleepiness. Due to their widespread availability, established efficacy, and physician familiarity, therapeutic drugs remain the cornerstone of treatment strategies for managing sleep disorders and associated symptoms, making them the dominant category.

Based on Distribution channels, the excessive daytime sleepiness market has been segmented into Hospitals & Sleep Laboratories, Home Care Settings. Hospitals & Sleep Laboratories segment was attributed to holding the largest market share in 2022. The dominant category is Hospitals & Sleep Laboratories, These facilities serve as essential hubs for the diagnosis, treatment, and management of sleep disorders contributing to excessive daytime sleepiness. Hospitals with specialized sleep clinics and laboratories offer comprehensive sleep studies, including polysomnography and multiple sleep latency tests, to accurately diagnose conditions such as obstructive sleep apnea (OSA), narcolepsy, and restless legs syndrome.

Regional Analysis

The excessive daytime sleepiness market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe excessive daytime sleepiness market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The excessive daytime sleepiness market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World excessive daytime sleepiness market comprises of Middle East, Africa, and Latin America.

The largest market share for excessive daytime sleepiness was maintained by the North American regional sector. This increase is attributed to the region has a high prevalence of sleep disorders, including obstructive sleep apnea, which often leads to excessive daytime sleepiness. Additionally, there is greater awareness and diagnosis of sleep disorders in North America compared to other regions, leading to higher demand for treatments and management options.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for excessive daytime sleepiness is driven by increasing awareness and recognition of sleep disorders, including excessive daytime sleepiness, among healthcare professionals and the general population in Europe. This heightened awareness has led to a greater number of individuals seeking diagnosis and treatment for their sleep-related issues.

Additionally, Asia Pacific is anticipated to experience the quickest growth in the excessive daytime sleepiness market due to several factors. Firstly, there is a growing awareness of sleep disorders and their impact on overall health and productivity in the region. As lifestyles become more hectic and stressful, there is an increasing prevalence of sleep-related issues, including excessive daytime sleepiness, driving the demand for diagnosis and treatment options.

Furthermore, the rest of the world's excessive daytime sleepiness market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the diverse populations with varying cultural, socioeconomic, and environmental factors influencing sleep patterns and overall health. Additionally, there may be unique challenges in accessing healthcare services and obtaining accurate diagnoses for sleep disorders in these regions, leading to different market dynamics compared to more developed regions.

Key Findings of the Study

• The excessive daytime sleepiness market is expected to reach USD 9.72 billion by 2032, at a CAGR of 7.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the growing awareness of sleep disorders and their impact on overall health and productivity in the region.


• Based on distribution channels, the hospitals & sleep laboratories segment was attributed to holding the largest market in 2022, with an approximate market share of 40–55%.


• Teva Pharmaceutical Industries Ltd.,GE Healthcare , Jazz Pharmaceuticals, Compumedics Fisher & Paykel Healthcare, BIOPROJET, BMC Medical Co. Ltd., Avadel Pharmaceuticals plc , Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer.